News | July 13, 2022
Piramal Pharma Solutions holds opening ceremony for new API Plant at Aurora, Canada
Plant is part of the company's CAD $30 million capital investment in the site
Plant is part of the company's CAD $30 million capital investment in the site
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
The vagus nerve is the longest nerve in the body that travels down from the brain to innervate and control breathing, stress levels and inflammation
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
Subscribe To Our Newsletter & Stay Updated
